Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Praxis Precision Medicines Inc
(NQ:
PRAX
)
58.42
+0.48 (+0.83%)
Streaming Delayed Price
Updated: 3:40 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
248,917
Open
58.00
Bid (Size)
58.40 (2)
Ask (Size)
58.60 (2)
Prev. Close
57.94
Today's Range
58.00 - 59.72
52wk Range
13.01 - 67.21
Shares Outstanding
44,712,538
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
September 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
September 04, 2024
Via
Benzinga
Performance
YTD
+179.52%
+179.52%
1 Month
+12.74%
+12.74%
3 Month
+42.18%
+42.18%
6 Month
+5.85%
+5.85%
1 Year
+184.28%
+184.28%
More News
Read More
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
September 04, 2024
Via
Benzinga
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 04, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
What 6 Analyst Ratings Have To Say About Praxis Precision Medicine
August 05, 2024
Via
Benzinga
Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews
June 18, 2024
Via
Benzinga
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
September 03, 2024
Via
Benzinga
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
September 03, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
September 02, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
August 14, 2024
Via
Benzinga
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024
August 13, 2024
Via
InvestorPlace
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
August 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Are We Having Fun Yet? Stocks Sell Off On Massive Volume
August 03, 2024
Via
Talk Markets
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
Via
Investor's Business Daily
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
Via
Benzinga
Quarterly & Long-Term Portfolios For The Win
July 06, 2024
Via
Talk Markets
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
June 24, 2024
Via
Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
June 20, 2024
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 20, 2024
Via
Benzinga
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
May 17, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
May 16, 2024
Via
Benzinga
PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024
May 13, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.